Rei Ohnishi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rei Ohnishi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Akira Yamada
Cancer Vaccine Development Division, Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Japan
1 shared publication - Fukuko Moriya
Department of Pathology, Kurume University School of Medicine
1 shared publication - Kyogo Itoh
Department of Immunology and Immunotherapy, Kurume University School of Medicine
1 shared publication - Masanori Noguchi
Department of Urology, Kurume University School of Medicine, Kurume, Japan
1 shared publication - Satoko Matsueda
Department of Immunology and Immunotherapy, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan
1 shared publication - Shigetaka Suekane
Department of Urology, School of Medicine, Kurume University, Kurume 830-0011, Japan
1 shared publication
Latest Publications
- Open Access
- 30 December 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 613
A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
Cancer vaccine is one of the attractive treatment modalities for patients with castration-resistant prostate cancer (CRPC). However, because of delayed immune responses, its clinical benefits, besides for overall survival (OS), are not well captured by the World Health Organization (WHO) and Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Several surrogate markers for evaluation of cancer vaccine, including prostate-specific antigen doubling time (PSADT), are currently sought. The purpose of this study was to assess prospectively the PSA kinetics and immune responses, as well as the efficacy, safety, and biomarkers of personalized peptide vaccination (PPV) in progressive CRPC.
- 30 December 2013
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 613
Open AccessA phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
Cancer vaccine is one of the attractive treatment modalities for patients with castration-resistant prostate cancer (CRPC). However, because of delayed immune responses, its clinical benefits, besides for overall survival (OS), are not well captured by the World Health Organization (WHO) and Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Several surrogate markers for evaluation of cancer vaccine, including prostate-specific antigen doubling time (PSADT), are currently sought. The purpose of this study was to assess prospectively the PSA kinetics and immune responses, as well as the efficacy, safety, and biomarkers of personalized peptide vaccination (PPV) in progressive CRPC.